The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma.

Hepatocellular carcinoma (HCC) is the fifth most common type of cancer and the third leading cause of cancer-related deaths worldwide. Liver resection or liver transplantation is the most effective therapy for HCC because drugs approved by the US Food and Drug Administration to treat patients with unresectable HCC have an unfavorable overall survival rate. Therefore, the development of biomarkers for early diagnosis and effective therapy strategies are still necessary to improve patient outcomes. Fibroblast growth factor (FGF) 19 was amplified in patients with HCC from various studies, including patients from The Cancer Genome Atlas. FGF19 plays a syngeneic function with other signaling pathways in primary liver cancer development, such as epidermal growth factor receptor, Wnt/ß-catenin, the endoplasmic reticulum-related signaling pathway, STAT3/IL-6, RAS, and extracellular signal-regulated protein kinase, among others. The current review presents a comprehensive description of the FGF19 signaling pathway involved in liver cancer development. The use of big data and bioinformatic analysis can provide useful clues for further studies of the FGF19 pathway in HCC, including its application as a biomarker, targeted therapy, and combination therapy strategies.

A new species of Pupinidius Möllendorff, 1901 (Gastropoda, Stylommatophora, Enidae) from Jiuzhaigou, Sichuan, China.

Background: The genus Pupinidius Möllendorff, 1901 is endemic in China and Nepal and consists of 15 species. China is the distribution centre of it with 12 species being recorded. New information: A new species, Pupinidiuspulchellus Chen, Dai, Wu & Ouyang sp. nov. is described from Jiuzhaigou, Sichuan, China. It can be distinguished from congeneric species by the shell with wide and distinct radial stripes; the thin, slightly reflexed and reddish-brown peristome; the unpointed apex; the unfused A-1 and A-2; the sub-globular and well defined bursa copulatrix; the unexpanded diverticle and the presence of epiphallic caecum.

Land snail diversity in central China: revision of Laeocathaica Möllendorff, 1899 (Gastropoda, Camaenidae), with descriptions of seven new species.

Central China harbors the native dart-sac-bearing camaenids Laeocathaica. The genus is revised and seven new species are proposed based on museum material and newly collected specimens. This work confirmed that most Laeocathaica species have restricted habitats. The comparison of the dart sac apparatus among the dart-sac-bearing camaenid genera indicated the importance of the presence of the proximal accessory sac that might be analogous to the membranous/muscular sac surrounding the proximal dart sac and/or the distal region of the vagina near the atrium, which also plays a significant role in the diagnosis of Laeocathaica species based on its number, symmetry and position on the dart sac. Species with similar shell morphology were studied using geometric morphometric methods to detect variations in shell shape. A molecular phylogenetic analysis based on 16S and ITS2 sequence data of partial Laeocathaica species and many other dart-sac-bearing taxa suggested that Laeocathaica might be monophyletic. Furthermore, the present phylogeny indicated that Stilpnodiscus, Cathaica, Bradybaena, and Pseudobuliminus might be polyphyletic and therefore the taxonomy of dart-sac-bearing camaenids in this region requires a thorough revision. This work reconfirms that the Southern Gansu Plateau is important as a hotspot for malacodiversity conservation on the Chinese mainland.

Unveiling the identity of Diaurora Cockerell, 1903 (Bivalvia, Unionidae): morphology, molecular phylogenetics, and the description of a new species.

The monotypic freshwater mussel genus Diaurora Cockerell, 1903 has long been enigmatic due to its rarity and morphological confusion with Acuticosta. In this study, we comprehensively redescribed Diauroraaurorea (Heude, 1883) through a detailed analysis of shell morphology and molecular phylogenetics of recently collected specimens. Moreover, a new species, Diauroralaevesp. nov., was identified from the Fuyishui River, a tributary of the Zishui River in Shaoyang County, Shaoyang City, Hunan Province, China. Molecular phylogenetic analyses showed that D.aurorea and D.laevesp. nov. were reciprocally monophyletic and formed a clade as sister to Schistodesmus. Our study underscores the necessity of further exploring the diversity of freshwater mussels in understudied small tributaries throughout China.

emLiobagrus/em emhuaiheensis/em, a new species of torrent catfish (Teleostei: Siluriformes: Amblycipitidae) from the Huaihe River basin in Central China.

Liobagrus huaiheensis, a new species of catfish, is described from the Shihe River, a tributary of the Huaihe River, in Henan Province, Central China. It shares a serrated posterior edge of the pectoral-fin spine with L. marginatus, L. nigricauda, L. kingi, L. chenghaiensis, L. andersoni, L. mediadiposalis, L. obesus, L. somjinensis, and L. hyeongsanensis, but it is distinguished from these nine species by having combination of the following characters: 2-3 serrations on the posterior edge of the pectoral-fin spine; 15-17 anal-fin rays; an upper jaw longer than lower one; a rounded caudal-fin with 50-55 rays; 35-37 post-Weberian vertebrae; anus close to pelvic-fin insertion and an adipose-fin posteriorly continuous with caudal-fin, with a marked incision at confluence.

Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors.

Introduction: Surufatinib (also known as HMPL-012, sulfatinib) is a novel oral tyrosine kinase inhibitor (TKI), which has the dual activity of anti-angiogenesis and immune regulation. In December 2020, surufatinib was approved as a monotherapy for unresectable locally advanced or metastatic, progressive nonfunctioning, well differentiated (grade 1 or 2) extrapancreatic neuroendocrine tumors (epNETs) in China.Areas covered: In this paper, the chemical properties, mechanism of action, pharmacokinetics, clinical efficacy, safety, and tolerability of surufatinib for treatment of advanced extrapancreatic NETs are introduced in detail. We performed a systematic review of the literature in PubMed and the following keywords were used: 'surufatinib,' 'sulfatinib' and 'HMPL-012.'Expert opinion: Surufatinib is a potent, selective, and small-molecule TKI that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor 1 (FGFR1) and colony stimulating factor 1 receptor (CSF1R). Surufatinib showed an acceptable safety profile and encouraging antitumor activity in patients with advanced epNETs. The most frequently observed adverse events (AEs) were hypertension and proteinuria. Surufatinib provides a new treatment option for patients with advanced epNETs. More clinical trials of surufatinib are ongoing to develop a combination of therapy strategies and new indications for malignancies.

The clinical application of camrelizumab on advanced hepatocellular carcinoma.

INTRODUCTION: Camrelizumab (also known as SHR-1210), a humanized monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1 and consequently inhibit the immune escape of tumor cells. Recently, camrelizumab was approved as a second-line drug for previously treated advanced hepatocellular carcinoma in China. AREAS COVERED: In this paper, the chemical properties, mechanism of action, pharmacokinetics, clinical efficacy, safety, and tolerability of camrelizumab for the treatment of advanced hepatocellular carcinoma are introduced in detail. The strategy for combination therapy and the potential application of camrelizumab in other solid tumors are briefly described. We performed a systematic review of the literature in PubMed and the following keywords were used: 'SHR-1210,' 'Camrelizumab,' and 'hepatocellular carcinoma.' EXPERT OPINION: Camrelizumab is a selective, humanized, high-affinity IgG4 kappa mAb against PD-1. Camrelizumab showed promising antitumor activity and manageable toxicities and offers a new second-line drug option for patients with advanced hepatocellular carcinoma. Reactive cutaneous capillary endothelial proliferation is a novel but prevalent immune-related dermatologic toxicity of camrelizumab, which is mild, reversible, and predictable. More clinical trials of camrelizumab are ongoing to develop combination therapy strategies and new indications for malignancies.

An easy synthesis of nitrogen and phosphorus co-doped carbon dots as a probe for chloramphenicol.

Heteroatom doping in carbon dots (CDs) was found to be an efficient way to regulate the structure of electronic energy levels and enhance the fluorescence characteristics of CDs. Nevertheless, most reported fabrication processes of heteroatom-doped CDs are rigorous and complex. Herein, a facile and novel strategy was developed to rapidly prepare nitrogen and phosphorus co-doped CDs (N,P-CDs) using acetic acid as the carbon source, and arginine, 1,2-ethylenediamine (EDA) and diphosphorus pentoxide as the dopants, respectively. The optical, morphological and structural characterizations of the synthesized N,P-CDs were investigated via UV and photoluminescence spectroscopy, X-ray photoelectron spectroscopy, TEM, and FT-IR spectroscopy. The N,P-CDs display outstanding fluorescence stability under high ionic strength (1.6 M KCl), and long time UV irradiation, indicating that they can be used as favorable candidates for fluorescent probes. The fluorescence of N,P-CDs was selectively quenched by chloramphenicol (CAP) with a short response time. The linear range of the response to CAP was from 0.8 to 70 µM with a limit of detection of 0.36 µM (S/N = 3). Notably, the fabricated N,P-CDs were employed for the highly selective and sensitive detection of CAP in milk samples, indicating their potential applications in biologically related areas.

The clinical application of fruquintinib on colorectal cancer.

Introduction: Anti-angiogenetic agents are currently the most commonly used drugs for the treatment of colorectal cancer (CRC) patients, including various inhibitors targeting the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and VEGF receptors (VEGFRs). Fruquintinib (HMPL-013), a highly selective and long-term small-molecule inhibitor of VEGFR (VEGFR1, 2, and 3) was recently approved in China for CRC treatment. Clinical studies have shown it has many advantages, such as low off-target toxicity, good drug tolerance, and strong effect. Areas covered: In the review, the molecular structure, mechanism of action, pharmacokinetics, clinical efficacy, and safety of fruquintinib are introduced in detail. The potential clinic application on non-small cell lung cancer (NSCLC) and gastric cancer is also discussed. Expert commentary: Fruquintinib was approved for patients with metastatic colorectal cancer (RAS wild type) who have previously received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy and who have received or are not suitable for anti- VEGF therapy and anti- EGFR therapy. As a novel, therapeutic approach to CRC, Fruquintinib could be used as a third-line drug for the treatment of CRC patients. Due to drug resistance during the long-term therapy, the combination of fruquintinib with other targeted therapy drugs may be an effective option for CRC treatment.

[Efficacy Analysis of GEMOX Regimen for Treatment of Refractory Non-Hodgkin's Lymphoma].

OBJECTIVE: To explore the clinical efficacy of GEMOX regimen on patients with refractory non-hodgkin's lymphoma. METHODS: Eighty-two cases of non-Hodgkin's lymphoma were divided into 2 groups: gemcitabine+oxaliplation(Gem+Oxa) group (42 cases) and vinorelbine+oxaliplatin(Vin+Oxa) group (40 cases) according to chemotherapy regimens. The clinical efficacy, side effects, progression-free survival situation in 2 groups were compared. RESULTS: There was no significant difference on the clinical effects of 2 groups (P>0.05); The therapeutic efficacy for B cell lymphoma was higher than that for T cell lymphoma(P<0.05); The therapeutic effects for I-II stages was lower than that for III-IV stages(P<0.05); The incidences of platelet decline, nausea and vomit, peripheral nerve symptoms in Gem+Oxa group were lower than those in Vin+Oxa group(P<0.05); There was no significant difference in the median progression free survival(P>0.05). CONCLUSION: The efficacy of GEMOX regimen for refractory non-Hodgkin's lymphoma has been confirmed to be good, it has distinct clinical curative effect, it can prolong the progression-free survival time in patients with B cell lymphoma, specially for III-IV stages. It can be used as the preferred method for the treatment of patients with refractory NHL.